Brief: Valbiotis Updates On REVERSE-IT Clinical Study On TOTUM-63

Valbiotis SA

15/07/2020 17:27

July 15 (Reuters) - VALBIOTIS SA  ALVAL.PA :
    * VALBIOTIS ANNOUNCES THE FIRST PATIENT FIRST VISIT IN THE
INTERNATIONAL PHASE II/III REVERSE-IT CLINICAL STUDY ON TOTUM-63
TO REDUCE TYPE 2 DIABETES RISK FACTORS
    * FIRST DEVELOPMENT MILESTONE PAYMENT OF CHF 3 MILLION FROM
NESTLÉ
HEALTH SCIENCE
    * INTERNATIONAL REVERSE-IT STUDY WILL INCLUDE 600 SUBJECTS
WITH
ALTERED GLUCOSE METABOLISM
    * ITS PRIMARY ENDPOINT IS FASTING GLYCEMIA AND IT WILL BE
LED IN
MORE THAN 30 CENTERS IN FRANCE AND ABROAD
    * REVERSE-IT STUDY RESULTS ARE EXPECTED IN MID-2022

Source text for Eikon:  ID:nBw9PkbFya 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))